Search
Advertisement
Hindustan Zinc, DRL & PB Fintech to share Q4 results shortly; here are earnings previews

Hindustan Zinc, DRL & PB Fintech to share Q4 results shortly; here are earnings previews

HINDZINC594.90(3.66%)

DRL Q4 results preview: Nirmal Bang sees US revenue for the drug maker rising 23 per cent YoY to $378 million on account of a lower base last year.

Amit Mudgill
Amit Mudgill
  • Updated May 7, 2024 11:57 AM IST
Hindustan Zinc, DRL & PB Fintech to share Q4 results shortly; here are earnings previewsHindustan Zinc: Motilal Oswal sees profit dropping 24.8 per cent YoY to Rs 1,942.80 crore on 6.4 per cent YoY fall in sales at Rs 7,963 crore. The brokerage said any guidance on future dividend payout is important.

A couple of companies including Hindustan Zinc Ltd, Dr Reddy's Laboratories Ltd (DRL) and PB Fintech Ltd (Policybazaar) are scheduled to report their quarterly earnings today. While Policybazaar is seen reporting a higher profit sequentially, Hindustan Zinc may report nearly 25 per cent fall in YoY profit, brokerage estimates suggested. DRL is seen reporting a 24 per cent rise in the bottom line, a brokerage said.

Advertisement

PB Fintech Q4 results
Dolat Capital expects PB Fintech to report a profit after tax of Rs 55.80 crore against a profit of Rs 37.20 crore in the December and a loss of Rs 9.40 crore in the same quarter last year. It sees sales at Rs 1,003.80 crore against Rs 869.10 crore in the year-ago quarter, up 15.3 per cent YoY, led by protection business. Any commentary on use of cash, overall insurance & lending growth outlook and overview on Reinsurance & payments business would be keenly watched.

Hindustan Zinc Q4 results
In the case of Hindustan Zinc, Motilal Oswal sees profit dropping 24.8 per cent YoY to Rs 1,942.80 crore on 6.4 per cent YoY fall in sales at Rs 7,963 crore. The brokerage said any guidance on future dividend payout is important.

Advertisement

"We await further insights on any other update related to the change in corporate structure, if any," it said while adding that guidance on CoP, volumes and realisations are also critical.

DRL Q4 results
In the case of Dr Reddy's Labs, revenue is expected to grow 12 per cent YoY. Nirmal Bang sees US revenue for the drug maker rising 23 per cent YoY to $378 million on account of a lower base last year. India business is expected to grow at 8 per cent  YoY. EBITDA margin is expected to improve 172 bps YoY to 26 per cent on account of reduced pricing pressure in the US business. It sees profit rising 23.8 per cent at Rs 1,187 crore. Sales is seen at Rs 7,037 crore.

Disclaimer: Business Today provides stock market news for informational purposes only and should not be construed as investment advice. Readers are encouraged to consult with a qualified financial advisor before making any investment decisions.
Follow us on

ABOUT THE AUTHOR

Amit Mudgill
Amit Mudgill

A financial journalist with over 18 years of experience in print and digital media, I cover India's capital markets, focusing on stocks, IPOs, mutual funds, corporate earnings, and market trends. Currently with Business Today, I report on equities, corporate developments, fundraising activity, and the broader investment landscape, delivering timely, data-backed insights to investors and readers.

Previously, I worked with The Economic Times and Deccan Chronicle, covering business, markets, and corporate affairs. My experience spans breaking news, analysis, and long-form features, with a strong focus on financial markets and investment-related reporting.

I am on the go 24/7:  Saying 'Good Night' to Dow Jones and 'Good Morning' to Gift Nifty comes naturally. Ask me about data and you'll hear stories. Away from markets, I enjoy stargazing, astrophotography, reading about India's neighbourhood, and playing video games.

Published on: May 7, 2024 11:57 AM IST